Intracardiac Erythropoietin Injection Reveals Antiinflammatory Potential and Improved Cardiac Functions Detected by Forced Swim Test

Transplantation Proceedings

Volumn 40, Issue 4, 2008, Pages 962-966

  Furlani, D ^a   Klopsch, C ^a   Gabel R ^a   Ugurlucan, M ^a   Pittermann, E ^a   Klee, D ^d   Wagner, K ^b   Li, W ^a   Wang, W ^a   Ong, L L ^a   Nizze, H ^a   Titze, U ^a   Lutzow K ^c   Lendlein, A ^c   Steinhoff, G ^a   Ma, N ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b Klinikum Sudstadt   (Germany)

^c INSTITUTE OF MATERIALS RESEARCH   (Germany)

^d RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTEGRIN; CYCLIN DEPENDENT KINASE 4; RECOMBINANT ERYTHROPOIETIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FORCED SWIMMING TEST; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE PERFORMANCE; HEART VENTRICLE SIZE; MEDICAL ASSESSMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THERAPY EFFECT; THROMBOGENESIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; CORONARY VESSELS; ERYTHROPOIETIN; HEART; HEART FUNCTION TESTS; HUMANS; INTEGRIN BETA CHAINS; PHYSICAL CONDITIONING, ANIMAL; RATS; RATS, INBRED LEW; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SWIMMING;

EID: 44849131117     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.03.033     Document Type: Article

References (14)

1. Sasaki A., Yasukawa H., Shoda T., et al. CIS3/SOCS3 suppresses EPO signalling by binding the EPO receptor and JAK2. J Biol Chem 275 (2000) 29338
2. Buemi M., Aloisi C., Cavallaro E., et al. Recombinant human erythropoietin (rHuEPO): more than just the correction of uremic anemia. J Nephrol 15 (2002) 97
3. Ehrenreich H., Hasselblatt M., Dembowski C., et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8 (2002) 495
4. Henry D.H., Bowers P., Romano M.T., et al. EPOetin alfa. Clinical evolution of a pleiotropic cytokine. Arch Intern Med 164 (2004) 262
5. Guo Y., and Kyprianou N. Restoration of transforming growth factor beta signalling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Cancer Res 59 (1999) 1366
6. Petit-Demouliere B., Chenu F., and Bourin M. Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology 177 (2005) 245 (Berl)
7. Takagawa J., Zhang Y., Wong M.L., et al. Myocardial infarct size measurement in the mouse chronic infarction model: comparison of area- and length-based approaches. J Appl Physiol 102 (2007) 2104
8. Mocini D., Leone T., Tubaro M., et al. Structure, production and function of erythropoietin: implications for therapeutical use in cardiovascular disease. Curr Med Chem 14 (2007) 2278
9. Van der Meer P., Voors A.A., Lipsic E., et al. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 44 (2004) 63
10. Gao E., Boucher M., Chuprun J.K., et al. DarbEPOetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart. Am J Physiol Heart Circ Physiol 293 (2007) H60
11. Zhang D., Zhang F., Zhang Y., et al. Erythropoietin enhances the angiogenic potency of autologous bone marrow stromal cells in a rat model of myocardial infarction. Cardiology 9 108 (2006) 228
12. Prunier F., Pfister O., Hadri L., et al. Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol 292 (2007) H522
13. Vitellaro-Zuccarello L., Mazzetti S., Madaschi L., et al. Erythropoietin-mediated preservation of the white matter in rat spinal cord injury. Neuroscience 144 (2007) 865 9
14. Nishiya D., Omura T., Shimada K., et al. Effects of erythropoietin on cardiac remodeling after myocardial infarction. J Pharmacol Sci 101 (2006) 31